nvro-ex991_40.htm

Redwood City, Calif., February 21, 2019 - Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the fourth quarter and full year ended December 31, 2018.

Revenue for the fourth quarter of 2018 was $107.9 million, a 10% increase compared to $98.0 million during the prior year quarter. U.S. revenue for the fourth quarter of 2018 was $91.6 million, a 13% increase over $81.1 million in the prior year period. International revenue was $16.3 million, compared to $16.9 million in the prior year period, which was a 1% increase on a constant currency basis or a 4% decrease on an as-reported basis. The increase in U.S. revenue was primarily attributable to the continued adoption of the Senza system.

Gross profit for the fourth quarter of 2018 was $76.2 million compared to $69.5 million in the prior year period. Gross margins were 70.5% in the fourth quarter of 2018 compared to 71.0% in the prior year period.

Operating expenses for the fourth quarter of 2018 were $84.8 million, an 18% increase compared to $71.7 million in the prior year period. Higher operating expenses were primarily driven by increased headcount and related costs.

Loss from operations for the fourth quarter of 2018 was $8.6 million compared to $2.2 million for the same period of the prior year.

Revenue for the full year 2018 was $387.3 million, a 19% increase, as reported, compared to $326.7 million in 2017. U.S. revenue was $321.8 million, a 22% increase compared to $263.5 million in the prior year. International revenue was $65.5 million compared to $63.2 million in 2017, which was a 2% increase on a constant currency basis or a 4% increase on an as-reported basis.

Gross profit for the full year 2018 was $273.3 million, a 20% increase compared to $227.7 million in 2017. Gross margins were 70.6% for the full year 2018, a 90-basis point increase compared to 69.7% gross margin in 2017.

Operating expenses for the full year 2018 were $315.1 million, a 22% increase compared to $257.3 million in 2017. Higher operating expenses were primarily driven by increased headcount and related costs especially in the second half of 2018.

Loss from operations for the full year 2018 was $41.7 million, a 41% increase compared to $29.6 million in 2017.

The balance of cash, cash equivalents and short-term investments was $264.5 million as of December 31, 2018 compared to $269.3 million at December 31, 2017.

Nevro expects 2019 worldwide revenue in the range of $400 to $410 million, which anticipates growth in U.S. revenues partially offset by declines in reported international revenue, primarily driven by reimbursement changes in Australia.

Management will host a conference call today beginning at 1:30 p.m. PT / 4:30 p.m. ET. Investors interested in listening to the conference call may do so by dialing (833) 286-5807 in the U.S. or (647) 689-4452 internationally, using Conference ID: 6773635. In addition, a live webcast will be available on the “Investors” section of the company’s website at: www.nevro.com and will also be archived there.

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

In addition to historical information, this press release contains forward-looking statements with respect to our business, capital resources, revenue projections, strategic initiatives and growth, reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including continuing adoption of, and interest in, Senza in the U.S. and international markets; and our expectations for worldwide revenue for the full year 2019. These forward-looking statements are based upon information that is currently available to us or our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including our ability to successfully commercialize our products; our ability to manufacture our products to meet demand; the level and availability of third-party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These factors, together with those that are described in greater detail in our Annual Report on Form 10-K that we expect to file on February 21, 2019, as well as any reports that we may file with the SEC in the future, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. Our results for the full year and quarter ended December 31, 2018 are not necessarily indicative of our operating results for any future periods.

	Three Months Ended						Year Ended
	December 31,						December 31,
	2018			2017			2018			2017
	(unaudited)
Revenue	$	107,944		$	97,963		$	387,289		$	326,674
Cost of revenue		31,790			28,451			113,965			98,981
Gross profit		76,154			69,512			273,324			227,693
Operating expenses:
Research and development		13,480			9,943			48,459			37,560
Sales, general and administrative		71,277			61,741			266,608			219,712
Total operating expenses		84,757			71,684			315,067			257,272
Loss from operations		(8,603	)		(2,172	)		(41,743	)		(29,579	)
Other income (expense):
Interest income (expense), net		(1,194	)		(1,616	)		(5,530	)		(6,738	)
Other income (expense), net		(319	)		(131	)		(1,164	)		1,067
Loss before income taxes		(10,116	)		(3,919	)		(48,437	)		(35,250	)
Provision for (benefit from) income taxes		(509	)		392			768			1,408
Net loss		(9,607	)		(4,311	)		(49,205	)		(36,658	)
Changes in foreign currency translation adjustment		(141	)		(319	)		(37	)		(360	)
Changes in gains (losses) on short-term investments		11			(311	)		202			(204	)
Net change in other comprehensive loss		(130	)		(630	)		165			(564	)
Comprehensive Loss	$	(9,737	)	$	(4,941	)	$	(49,040	)	$	(37,222	)
Net loss per share, basic and diluted	$	(0.32	)	$	(0.15	)	$	(1.64	)	$	(1.25	)
Weighted average shares used to compute net loss per share, basic and diluted		30,214,454			29,664,926			30,051,961			29,424,054

	December 31,			December 31,
	2018			2017

Assets
Current assets
Cash and cash equivalents	$	51,266		$	42,845
Short-term investments		213,281			226,467
Accounts receivable, net		80,656			67,287
Inventories, net		92,035			98,119
Prepaid expenses and other current assets		6,621			6,463
Total current assets		443,859			441,181
Property and equipment, net		12,801			8,819
Other assets		5,850			3,250
Restricted cash		606			806
Total assets	$	463,116		$	454,056
Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	23,505		$	18,492
Accrued liabilities and other		38,909			39,512
Total current liabilities		62,414			58,004
Long-term debt		152,394			145,019
Other long-term liabilities		2,825			1,861
Total liabilities		217,633			204,884
Stockholders’ equity
Common stock, $0.001 par value, 290,000,000 shares authorized, 30,263,536 and 29,737,561 shares issued and outstanding at December 31, 2018 and 2017, respectively		30			30
Additional paid-in capital		552,612			508,228
Accumulated other comprehensive loss		(1,077	)		(1,242	)
Accumulated deficit		(306,082	)		(257,844	)
Total stockholders’ equity		245,483			249,172
Total liabilities and stockholders’ equity	$	463,116		$	454,056